Metoklopramidklorid Hameln (Metoclopramide Hydrochloride Monohydrate)

Metoclopramide is used to manage conditions related to nausea, vomiting and delayed gastric emptying.

• Nausea and vomiting: reduces episodes in various clinical settings.
• Post‑operative nausea and vomiting: prevents and treats nausea after surgery.
• Gastroparesis: enhances gastric motility and relieves related symptoms.
• Chemotherapy‑induced nausea: helps control nausea associated with anticancer treatment.

• Metoclopramide blocks dopamine D2 receptors in the chemoreceptor trigger zone, diminishing the vomiting reflex. It also antagonizes peripheral D2 receptors, increasing acetylcholine release, which stimulates gastrointestinal smooth‑muscle contraction and accelerates gastric emptying, thereby improving motility and reducing nausea.

Metoclopramide may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Drowsiness: feeling unusually sleepy or fatigued.
• Restlessness: mild agitation or inner tension.
• Diarrhea: loose or frequent stools.
• Dry mouth: reduced salivation.

Serious or Rare Side Effects

• Extrapyramidal symptoms: involuntary muscle movements or dystonia.
• Neuroleptic malignant syndrome: rare, life‑threatening reaction with fever and rigidity.
• Tardive dyskinesia: persistent involuntary facial movements.
• Severe hypotension: marked drop in blood pressure.

Before using Metoklopramide, consider the following safety measures.

• Renal or hepatic impairment: assess function and adjust use accordingly.
• Extrapyramidal monitoring: watch for signs of muscle rigidity or tremor.
• Parkinson's disease: avoid or use with caution due to dopamine blockade.
• Known hypersensitivity: discontinue if allergic reaction occurs.
• Elderly patients: start with lower doses and monitor closely.
• Store at ambient temperature: keep in original packaging, protect from moisture.

Metoclopramide can interact with several medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid)

• Antipsychotics (e.g., haloperidol): may increase risk of extrapyramidal symptoms.
• MAO inhibitors: can potentiate central nervous system effects.
• CNS depressants (e.g., opioids, benzodiazepines): may enhance sedation.
• CYP2D6 inhibitors: may raise metoclopramide plasma levels.

Moderate Interactions (Monitor Closely)

• Anticholinergics: may reduce pro‑kinetic effect.
• SSRIs and tricyclic antidepressants: monitor for additive serotonergic activity.
• Diabetic agents: watch for masked hypoglycemia symptoms.